Erratum: A2780 human ovarian cancer cells with acquired paclitaxel resistance display cancer stem cell properties (Oncology Letters (2013) 6 (1295‑1298) DOI: 10.3892/ol.2013.1568);A2780 human ovarian cancer cells with acquired paclitaxel resistance display cancer stem cell properties

Oncology Letters

Volumn 6, Issue 5, 2013, Pages 1295-1298

  Han, Xiaofeng ^a   Du, Fangfang ^a   Jiang, Li ^a   Zhu, Yifei ^a   Chen, Zhen ^a   Liu, Yanjun ^a   Hong, Tingting ^a   Wang, Teng ^a   Mao, Yong ^a   Wu, Xiaohong ^a   Bruce, Iain C ^a   Jin, Jian ^a   Ma, Xin ^a   Hua, Dong ^a  

^a JIANGNAN UNIVERSITY   (China)

Author keywords

Aldehyde dehydrogenase 1; Cancer stem cells; Chemoresistance; Ovarian cancer; Paclitaxel

Indexed keywords

ALDEHYDE DEHYDROGENASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; CANCER CELL CULTURE; CANCER STEM CELL; CARCINOGENICITY; CELL ASSAY; CELL STRUCTURE; CHEMOSENSITIVITY; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; OVARY CANCER; PHENOTYPE; PROTEIN EXPRESSION;

EID: 84884497621     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2022.13526     Document Type: Erratum

References (24)

1. Aguilar-Gallardo C, Rutledge EC, Martínez-Arroyo AM, HidalgoJJ, Domingo S and Simón C: Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches. Stem Cell Rev 8: 994-1010, 2012.
2. Wang L, Mezencev R, Bowen NJ, Matyunina LV and McDonaldJF: Isolation and characterization of stem-like cells from a human ovarian cancer cell line. Mol Cell Biochem 363: 257-268, 2012.
3. Conic I, Dimov I, Tasic-Dimov D, Djordjevic B and StefanovicV: Ovarian epithelial cancer stem cells. Scientific World Journal11: 1243-1269, 2011.
4. Aletti GD, Gallenberg MM, Cliby WA, Jatoi A and HartmannLC: Current management strategies for ovarian cancer. Mayo Clin Proc 82: 751-770, 2007.
5. Diehn M, Cho RW, Lobo NA, et al: Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458: 780-783, 2009.
6. Clarke MF, Dick JE, Dirks PB, et al: Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339-9344, 2006.
7. Burgos-Ojeda D, Rueda BR and Buckanovich RJ: Ovarian cancer stem cell markers: Prognostic and therapeutic implications. Cancer Lett 322: 1-7, 2012.
8. Sullivan JP, Spinola M, Dodge M, et al: Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 70: 9937-9948, 2010.
9. Yu C, Yao Z, Dai J, et al: ALDH activity indicates increased tumorigenic cells, but not cancer stem cells, in prostate cancer cell lines. In Vivo 25: 69-76, 2011.
10. Wicha MS, Ginestier C, Charaffe-Jauffret E, Tarpin FI, Dontu G and Iovino F: Tumor invasion and metastasis of human breast cancer is mediated by the ALDH-1+stem cell component. Clin Exp Metastas 25: 11-11, 2008.
11. Steg AD, Bevis KS, Katre AA, et al: Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 18: 869-881, 2012.
12. Liu P, Brown S, Goktug T, et al: Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. Br J of Cancer 107: 1488-1497, 2012.
13. Croker AK, Goodale D, Chu J, et al: High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 13: 2236-2252, 2009.
14. Martelli AM, Evangelisti C, Chiarini F, et al: The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochim Biophys Acta 1803: 991-1002, 2010.
15. Dou J, Pan M, Wen P, et al: Isolation and identification of cancer stem-like cells from murine melanoma cell lines. Cell Mol Immunol 4: 467-472, 2007.
16. Chang A: Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 71: 3-10, 2011.
17. Yang H, Zhang Q, He J and Lu W: Regulation of calcium signaling in lung cancer. J Thorac Dis 2: 52-56, 2010.
18. Awad O, Yustein JT, Shah P, et al: High ALDH activity identifies chemotherapy-resistant Ewings sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One 5: e13943, 2010.
19. Cvek B: Comment on 'cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells'. Br J Cancer 108: 993, 2013.
20. Berry DA, Ueno NT, Johnson MM, et al: High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol 29: 3224-3231, 2011.
21. Jelski W, Kutylowska E, Laniewska-Dunaj M, Orywal K, Laszewicz W and Szmitkowski M: Alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) activity in the sera of patients with acute and chronic pancreatitis. Exp Mol Pathol 91: 631-635, 2011.
22. Deng S, Yang X, Lassus H, et al: Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 5: e10277, 2010.
23. Wang YC, Yo YT, Lee HY, et al: ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome. Am J Pathol 180: 1159-1169, 2012.
24. Amente S, Zhang J, Lavadera ML, Lania L, Avvedimento EV and Majello B: Myc and PI3K/AKT signaling cooperatively repress FOXO3a-dependent PUMA and GADD45a gene expression. Nucleic Acids Res 39: 9498-9507, 2011.